Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of August 2020, with a specific reporting date of August 13, 2020. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| 2020-08-11 | Ordinary Shares (25p each) | £15.9785 | 144 shares (aggregate) | London Stock Exchange (XLON) |
Note: The aggregate volume of 144 shares represents the sum of acquisitions by 12 individuals, consisting of "partnership shares" and "matching shares" acquired under the Share Reward Plan.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine equity compensation acquisitions by senior executives.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The document is a regulatory disclosure of specific share transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, not open market purchases or sales.
- Participants: Transactions involved 12 senior executives, including the CEO (Ms. E. Walmsley), President of Global Vaccines (Mr. R. Connor), and CEO of ViiV Healthcare (Ms. D. Waterhouse).
- Transaction Volume: Individual acquisitions were minimal, ranging from 14 to 16 shares per executive.
- Price Consistency: All transactions occurred at a uniform price of £15.9785 per share on August 11, 2020.
- Financial Data Absence: Investors should refer to GSK's Form 20-F or interim financial reports for revenue, profit, and liquidity data, as this filing contains none.